Table 3.
Ongoing randomized HIPEC trials in ovarian cancer.
| Country | PI | Phase | Time Point | Sample Size | Chemotherapy | Clinicaltrials.gov Identifier |
|---|---|---|---|---|---|---|
| South Korea | Chang | N/A | Primary | 204 | Paclitaxel | NCT03448354 |
| United States | Momeni | 1 | Recurrent | 20 | Carboplatin | NCT02672098 |
| Italy | Not provided | N/A | Recurrent | 158 | Cisplatin | NCT01538785 |
| Spain | Villarejo Campos | 3 | Primary or recurrent | 94 | Paclitaxel | NCT02681432 |
| China | Cui | 3 | Primary or recurrent | 214 | Paclitaxeland cisplatin | NCT03373058 |
| United States | Jewell | 2 | Primary | 20 | Cisplatin | NCT03321188 |
| Italy, Germany | Ansaloni | 3 | Primary | 94 | Cisplatin and paclitaxel | NCT01628380 |
| Mexico | Salcedo-Hernandez | 2 | Primary | 100 | Cisplatin and doxorubicin | NCT03275194 |
| Spain | Villarejo Campos | 3 | Primary or recurrent | 32 | Cisplatin | NCT02328716 |
| Belgium, France, Spain | Classe | 3 | Recurrent | 444 | Cisplatin | NCT01376752 |
| France | not provided | 3 | Recurrent | 220 | Cisplatin | NCT03220932 |
| United States | Zivanovic | 2 | Recurrent | 98 | Carboplatin | NCT01767675 |
| India | Solanki | N/A | Primary or recurrent | 150 | Not provided | NCT02754115 |
| United States | Sardi | 2 | Primary | 48 | Carboplatin | NCT02124421 |
| United States | Kelly | 2 | Primary or recurrent | 40 | Carboplatin | NCT03188432 |
| United States | Dellinger | 1 | Primary or recurrent | 5 | Cisplatin | NCT01970722 |
| Norway | Flatmark | Observational | Primary or recurrent | 200 | Not provided | NCT02073500 |
| Belgium | Ceelen | 2 | Primary or recurrent | 48 | Cisplatin | NCT02567253 |
| United States | Lilja | 2 | Recurrent | 200 | Cisplatin | NCT02349958 |
| France | Bereder | N/A | Primary or recurrent | 44 | Not provided | NCT02803515 |